Clobazam

For adults and pediatric patients weighing more than 30 kg, the dosing of clobazam is typically initiated at a low level and titrated upward to minimize side effects. According to the FDA-approved labeling, the standard starting dose is 10 mg per day, divided into two doses.

After one week, the dose may be increased to 20 mg per day (10 mg twice daily). Depending on the patient's clinical response and tolerability, the dose can be further increased at weekly intervals. The maximum recommended dose for patients over 30 kg is 40 mg per day. In some clinical trials, doses up to 80 mg were studied, but there is no evidence that doses above 40 mg provide additional benefit, while they significantly increase the risk of adverse reactions.

For pediatric patients (2 years and older) weighing 30 kg or less, dosing is weight-based. The starting dose is usually 5 mg once daily. After one week, this can be increased to 5 mg twice daily (10 mg total). In the third week, the dose may be increased to 20 mg per day (10 mg twice daily), which is generally the maximum recommended dose for this weight group.

It is vital that pediatric dosing be handled with extreme care, as children may be more sensitive to the sedative effects of benzodiazepines. Healthcare providers will monitor the child closely for signs of excessive sleepiness or changes in behavior during the titration period.

Renal Impairment

There is limited data on clobazam use in patients with severe renal impairment. While the drug is primarily metabolized by the liver, the metabolites are excreted by the kidneys. Healthcare providers generally do not require a specific dose adjustment for mild to moderate renal impairment, but caution is advised in patients with end-stage renal disease (ESRD).

Hepatic Impairment

Clobazam is extensively metabolized by the liver. For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), the starting dose should be reduced, and titration should proceed slowly. For patients with severe hepatic impairment (Child-Pugh Class C), clobazam is generally not recommended, or must be used with extreme caution at very low doses.

Elderly Patients

Patients over the age of 65 often have reduced metabolic capacity and may be more susceptible to the CNS-depressant effects of clobazam. The starting dose for elderly patients should be 5 mg per day, regardless of body weight, with very slow titration and frequent monitoring for falls or cognitive impairment.

CYP2C19 Poor Metabolizers

Patients who are known to be 'poor metabolizers' of the CYP2C19 enzyme will have significantly higher levels of the active metabolite, N-desmethylclobazam. For these individuals, the starting dose should be 5 mg per day, and titration should proceed at half the normal speed.

• Consistency: Clobazam can be taken with or without food, but it should be taken the same way every time to ensure consistent absorption.
• Tablets: Tablets can be swallowed whole, or they can be crushed and mixed with a small amount of applesauce. If crushed, the entire mixture must be consumed immediately.
• Oral Suspension: Always use the calibrated dosing syringe provided by the pharmacy. Do not use a household teaspoon. Shake the bottle vigorously for at least 10 seconds before measuring the dose.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place. Keep the bottle tightly closed.

If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never 'double up' on doses to make up for a missed one, as this significantly increases the risk of respiratory depression and extreme sedation.

An overdose of clobazam, especially when combined with alcohol or other CNS depressants, can be life-threatening. Symptoms of overdose include:

• Extreme drowsiness or lethargy
• Confusion
• Slurred speech
• Ataxia (loss of coordination)
• Hypotonia (decreased muscle tone)
• Respiratory depression (slow or shallow breathing)
• Coma

In the event of a suspected overdose, emergency medical services must be contacted immediately. Treatment typically involves supportive care, gastric lavage (if caught early), and in severe cases, the administration of flumazenil (a benzodiazepine antagonist), though flumazenil must be used with caution in seizure patients as it can precipitate status epilepticus.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as sudden discontinuation can cause severe withdrawal seizures.

Side effects are most common during the first few weeks of treatment as the body adjusts to the medication. According to clinical trial data, the most frequently reported adverse reactions include:

• Somnolence (Sleepiness): This is the most common side effect. Patients may feel excessively tired or have difficulty staying awake during the day. This effect is dose-dependent and often improves over time.
• Pyrexia (Fever): Particularly in pediatric populations, a low-grade fever may occur shortly after starting the medication.
• Upper Respiratory Tract Infections: Patients may experience symptoms similar to the common cold, including cough, nasal congestion, and sore throat.
• Lethargy and Fatigue: A general sense of weakness or lack of energy that can interfere with daily activities.
• Drooling (Sialorrhea): Increased saliva production is frequently noted, especially in children with LGS.

• Vomiting and Constipation: Gastrointestinal disturbances are relatively common and can usually be managed with dietary changes or supportive care.
• Ataxia: Problems with coordination, balance, or walking. This may feel like 'drunkenness' and increases the risk of falls.
• Aggression and Irritability: Some patients, particularly children, may experience paradoxical excitement or behavioral changes.
• Insomnia: While sedation is more common, some patients find it difficult to fall or stay asleep.
• Dysarthria: Difficulty speaking clearly or slurred speech.

• Diplopia: Double vision or other minor visual disturbances.
• Increased Appetite: Some patients may experience weight gain due to increased caloric intake.
• Urinary Retention: Difficulty passing urine or a feeling that the bladder is not empty.

> Warning: Stop taking Clobazam and call your doctor immediately if you experience any of these serious reactions.

• Serious Skin Reactions (SJS/TEN): Clobazam has been associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Symptoms include a painful red or purplish rash that spreads and blisters, often accompanied by fever and flu-like symptoms. This is a medical emergency.
• Respiratory Depression: Dangerously slow or shallow breathing. This risk is highest when clobazam is combined with opioids or alcohol.
• Suicidal Ideation: Like all antiepileptic drugs, clobazam may increase the risk of suicidal thoughts or behavior. Monitor for new or worsening depression, anxiety, or unusual changes in mood.
• Severe Allergic Reactions (Anaphylaxis): Symptoms include swelling of the face, lips, or tongue, difficulty breathing, and hives.
• Paradoxical Reactions: In rare cases, the drug may cause an increase in seizure frequency or severe agitation.

• Tolerance: Over time, the brain may become less sensitive to the effects of clobazam, meaning higher doses are required to achieve the same level of seizure control. This is a common issue with all benzodiazepines.
• Physical and Psychological Dependence: Long-term use leads to physical dependence. The body requires the drug to function normally, and stopping it abruptly will cause withdrawal.
• Cognitive Impairment: Some studies suggest that long-term benzodiazepine use may contribute to difficulties with memory, concentration, and processing speed.

The FDA has issued several boxed warnings for clobazam, the most serious level of warning:

1. 1Risks from Concomitant Use with Opioids: Taking clobazam with opioid pain or cough medicines can result in profound sedation, respiratory depression, coma, and death.
2. 2Abuse, Misuse, and Addiction: Clobazam exposes users to the risks of abuse and addiction, which can lead to overdose or death. Assess each patient's risk before prescribing.
3. 3Dependence and Withdrawal Reactions: Continued use may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction may precipitate life-threatening withdrawal reactions, including status epilepticus.

Report any unusual symptoms to your healthcare provider. Do not ignore changes in mood, skin condition, or breathing patterns.

Clobazam is a potent central nervous system (CNS) depressant. Patients and caregivers must be aware that this medication can significantly impair mental alertness and physical coordination. Activities requiring high levels of concentration, such as driving or operating heavy machinery, should be avoided until the patient is certain that the medication does not affect them adversely.

As of the latest FDA updates (2024), Clobazam carries a boxed warning regarding three critical risks:

• Concomitant use with Opioids: The combination of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
• Abuse and Addiction: Clobazam is a Schedule IV controlled substance. Use of clobazam, even as prescribed, exposes users to the risk of abuse and addiction.
• Withdrawal: To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clobazam or reduce the dosage.

Serious Dermatological Reactions

Clobazam can cause rare but fatal skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These reactions can occur at any time during treatment but are most likely during the first eight weeks. If a rash or mucosal lesions (sores in the mouth or eyes) develop, the drug should be discontinued immediately and not restarted.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including clobazam, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. This risk has been observed as early as one week after starting AEDs.

CNS Depression and Somnolence

Clobazam causes dose-dependent somnolence and sedation. In clinical trials, this was reported in up to 32% of patients. This effect is additive when combined with other CNS depressants, including alcohol, other benzodiazepines, and sedating antihistamines.

Patients on long-term clobazam therapy should undergo periodic monitoring, including:

• Liver Function Tests (LFTs): To ensure the liver is processing the drug effectively, especially in patients with pre-existing hepatic issues.
• Mental Health Screening: Regular assessment for signs of depression or suicidal ideation.
• Respiratory Function: In patients with pre-existing respiratory disease (like COPD or sleep apnea), monitoring for hypoventilation is necessary.

Patients should be advised not to drive or operate machinery until they have gained sufficient experience on clobazam to gauge whether it adversely affects their ability to drive or operate machinery. The degree of impairment is increased if alcohol is consumed.

Alcohol must be strictly avoided. Alcohol significantly increases the plasma levels of clobazam (by approximately 50%) and enhances its sedative effects, which can lead to dangerous levels of respiratory depression.

Clobazam must never be stopped abruptly. Doing so can cause 'rebound' seizures, which may be more severe than the original seizures, and can lead to status epilepticus (a prolonged seizure that is a medical emergency). Withdrawal symptoms can also include tremors, hallucinations, cramping, and insomnia. A tapering schedule, often lasting several weeks or months, is required.

> Important: Discuss all your medical conditions, including any history of depression, substance abuse, or respiratory problems, with your healthcare provider before starting Clobazam.

While few drugs are strictly contraindicated, the combination of Clobazam with Sodium Oxybate (used for narcolepsy) is generally avoided because both are potent CNS depressants that can lead to life-threatening respiratory suppression and extreme lethargy.

Opioids

The combination of clobazam and opioids (e.g., hydrocodone, oxycodone, morphine, fentanyl) is extremely dangerous. Both classes of drugs suppress the central nervous system's drive to breathe. If these must be used together, the lowest effective doses should be used for the shortest possible duration.

CYP2C19 Inhibitors

Clobazam's active metabolite, N-desmethylclobazam, is primarily cleared by the CYP2C19 enzyme. Drugs that inhibit this enzyme—such as Omeprazole (Prilosec) or Fluconazole—can cause the levels of the active metabolite to skyrocket, leading to increased toxicity and sedation. Dosage adjustments of clobazam may be necessary.

CNS Depressants

Other benzodiazepines (alprazolam, lorazepam), barbiturates, non-benzodiazepine hypnotics (zolpidem), and certain antipsychotics have additive effects with clobazam. Using these together increases the risk of sedation and impaired motor coordination.

CYP2D6 Substrates

Clobazam is a weak inhibitor of the CYP2D6 enzyme. This means it can increase the blood levels of drugs metabolized by this enzyme, such as Fluoxetine, Paroxetine, and certain beta-blockers. Healthcare providers may need to lower the dose of these medications when starting clobazam.

Hormonal Contraceptives

Clobazam is a weak inducer of the CYP3A4 enzyme. While the clinical significance is often low, there is a theoretical risk that clobazam could reduce the effectiveness of hormonal birth control pills, patches, or rings. Patients may wish to discuss backup contraception methods with their doctor.

• Alcohol: This is the most significant interaction. Alcohol increases the absorption of clobazam and slows its metabolism, leading to a 50% increase in drug levels. This can cause fatal respiratory depression.
• Grapefruit Juice: While clobazam is metabolized by CYP3A4, the effect of grapefruit juice is generally considered modest compared to other benzodiazepines, but caution is still advised as it may increase drug levels.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4 and can significantly lower the levels of clobazam in the blood, potentially leading to breakthrough seizures.
• Kava, Valerian, and Melatonin: These supplements have sedating properties and can increase the drowsiness caused by clobazam.
• CBD (Cannabidiol): CBD is a potent inhibitor of CYP2C19. Taking CBD (such as Epidiolex) with clobazam can increase the levels of the active metabolite N-desmethylclobazam by 3-fold to 5-fold, necessitating a significant reduction in clobazam dosage.

Clobazam does not typically interfere with standard laboratory tests, such as blood chemistry or urine analysis. However, it will result in a positive result on urine drug screens for benzodiazepines.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes over-the-counter medications like cold and flu syrups, which may contain alcohol or antihistamines.

Clobazam must NEVER be used in the following circumstances:

• Hypersensitivity: Patients with a known allergy to clobazam or any of the inactive ingredients in the tablets or suspension. An allergic reaction can manifest as hives, swelling, or anaphylaxis.
• Severe Respiratory Insufficiency: Because clobazam is a respiratory depressant, it can be fatal in patients who already have severely compromised lung function.
• Myasthenia Gravis: This is a neuromuscular disorder characterized by muscle weakness. Benzodiazepines like clobazam can further relax muscles, potentially leading to a crisis where the patient cannot breathe or swallow.
• Sleep Apnea Syndrome: Clobazam can worsen the frequency and duration of apneic episodes (periods where breathing stops during sleep).

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• History of Substance Abuse: Because clobazam is a Schedule IV drug with a risk for addiction and dependence, it should be used with extreme caution in individuals with a history of drug or alcohol use disorder.
• Severe Hepatic Impairment: The liver is responsible for clearing clobazam. In severe liver disease, the drug can accumulate to toxic levels, leading to hepatic encephalopathy or coma.
• Narrow-Angle Glaucoma: While more common with other benzodiazepines, clobazam should be used cautiously in patients with this condition as it may slightly increase intraocular pressure.
• Spinal or Cerebellar Ataxia: Since clobazam already impairs coordination, it can severely worsen the symptoms of pre-existing ataxia, leading to a high risk of falls.

Patients who have had a severe allergic reaction to other benzodiazepines (such as diazepam, lorazepam, or alprazolam) may be at an increased risk of a reaction to clobazam. While the chemical structure is slightly different (1,5-benzodiazepine vs 1,4-benzodiazepine), cross-reactivity is possible. Always inform your doctor of any previous drug allergies.

> Important: Your healthcare provider will evaluate your complete medical history, including respiratory health and history of addiction, before prescribing Clobazam.

Clobazam is associated with potential risks to the fetus. According to data from pregnancy registries and animal studies, benzodiazepines can cross the placenta. Use of clobazam during pregnancy may result in:

• Neonatal Withdrawal Syndrome: Infants born to mothers taking clobazam late in pregnancy may experience withdrawal symptoms such as irritability, tremors, and excessive crying.
• 'Floppy Infant Syndrome': This involves hypotonia (low muscle tone), lethargy, and feeding difficulties in the newborn.
• Teratogenicity: While data for clobazam specifically is less clear than for older benzodiazepines, there is a general concern regarding a slightly increased risk of cleft lip or palate if used in the first trimester.

Clobazam should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women of childbearing age should discuss family planning with their neurologist.

Clobazam and its active metabolite are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, such as extreme somnolence and feeding problems, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Clobazam is FDA-approved for the adjunctive treatment of seizures associated with LGS in children aged 2 years and older. Safety and effectiveness in children under the age of 2 have not been established. In pediatric patients, weight-based dosing is essential, and caregivers must be vigilant for signs of aggression or paradoxical hyperactivity, which are more common in this age group.

Clinical studies of clobazam did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients generally have a higher risk of falls and fractures due to the drug's effect on coordination. They are also more likely to have reduced renal or hepatic function. Dosing should start at the lowest possible level (5 mg) and be increased very slowly.

In patients with mild (creatinine clearance 60–89 mL/min) to moderate (30–59 mL/min) renal impairment, no dosage adjustment is generally required. In patients with severe renal impairment or ESRD, there is limited data, and clobazam should be used with caution as the metabolites may accumulate.

Clobazam is extensively metabolized by the liver.

• Mild to Moderate (Child-Pugh A/B): Start with 5 mg/day and titrate slowly.
• Severe (Child-Pugh C): Use is generally not recommended. If used, it requires extreme caution and very low doses.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.

Clobazam is a 1,5-benzodiazepine. Its primary mechanism involves the potentiation of GABAergic neurotransmission. It binds to the benzodiazepine site of the GABA-A receptor, which is a pentameric ion channel. By binding here, clobazam increases the affinity of the receptor for GABA, leading to an increase in the frequency of chloride channel opening. This results in hyperpolarization of the neuron and an overall inhibitory effect on the central nervous system. Clobazam's unique 1,5-structure is thought to provide a more favorable anticonvulsant-to-sedative ratio compared to 1,4-benzodiazepines.

The anticonvulsant effect of clobazam is dose-dependent. Onset of action is relatively rapid, with peak effects occurring within a few hours of the first dose. However, because of the long half-life of its active metabolite, the full clinical effect for seizure control may not be seen for 1 to 2 weeks. Tolerance to the anticonvulsant effects can develop, which is a significant limitation of long-term benzodiazepine therapy.

| Parameter | Value |

|---|---|

| Bioavailability | ~100% |

| Protein Binding | 80% - 90% |

| Half-life (Parent) | 36 - 42 hours |

| Half-life (Metabolite) | 71 - 82 hours |

| Tmax | 0.5 - 4 hours |

| Metabolism | Hepatic (CYP3A4, CYP2C19) |

| Excretion | Renal 82%, Fecal 11% |

• Molecular Formula: C16H13ClN2O2
• Molecular Weight: 300.74 g/mol
• Solubility: Slightly soluble in water; freely soluble in methylene chloride; sparingly soluble in ethanol.
• Structure: Clobazam consists of a 1,5-benzodiazepine ring system with a phenyl group at the 4-position and a chlorine atom at the 7-position.

Clobazam is classified as an anticonvulsant and anxiolytic within the benzodiazepine class. It is specifically a 1,5-benzodiazepine, distinguishing it from drugs like diazepam, clonazepam, and lorazepam, which are 1,4-benzodiazepines.